NEW YORK-- Pfizer said Thursday it is recalling some lots of its antidepressant Effexor XR because a single capsule of a different medication was found in one bottle of the drug. Pfizer is recalling two production lots of Effexor XR capsules and one lot of generic Effexor, or venlafaxine, sold by its Greenstone LLC subsidiary.» Read More
Pfizer is in clinical trials to create an over-the-counter version of cholesterol drug, Lipitor. Barbara Ryan, FTI Consulting, discusses challenges the pharmaceutical will face.
*Reinhardt at Novartis overhauling structure, culture. ZURICH, March 3- When outgoing Lufthansa chief executive Christoph Franz takes over as chairman of Swiss drugmaker Roche on Tuesday, it could be the start of a new era of less-frosty relations with arch-rival Novartis.
The Supreme Court will hear an appeal filed by Omnicare in a securities case filed by investors.
Here's what you need to know about this month's open enrollment countdown.
WASHINGTON, Feb 28- Generic drugmakers are furiously campaigning against a proposed U.S. rule that would require them to change the prescribing information on their products if they receive new safety information, which they say would open them to product liability lawsuits.
WASHINGTON _ The Commerce Department releases personal income and spending for January, 8:30 a.m. Eastern; Institute for Supply Management releases its manufacturing index for February, 10 a.m.; Commerce Department releases construction spending for January, 10 a.m.; House Energy and Commerce subcommittee hearing on proposed changes to generic drug labeling.
WASHINGTON _ Commerce Department releases personal income and spending for January, 8:30 a.m. Eastern; Institute for Supply Management releases its manufacturing index for February, 10 a.m.; Commerce Department releases construction spending for January, 10 a.m.; House Energy and Commerce subcommittee hearing on proposed changes to generic drug labeling.
LONDON, Feb 28- Gains at major German drugmaker Bayer helped to prop up European equities on Friday, although weak earnings in Spain hit the Madrid market. Spanish builders FCC and Sacyr fell 7.2 percent and 3.1 percent respectively after each reported losses for 2013..
Medivation Inc. tumbled in premarket trading Friday, a day after the drugmaker forecast 2014 revenue from its prostate cancer treatment Xtandi that fell short of analyst expectations. Medivation also is studying the drug as a possible treatment for patients before chemotherapy, a broader use that would boost sales.
LEVERKUSEN, Germany, Feb 28- Germany's largest drugmaker Bayer lifted its estimate for potential sales of new drugs by billions of euros on Friday, softening the blow of a fall in fourth-quarter earnings.
Discussing the regulations for affordable medicine, with Mylan CEO Heather Bresch. She also discusses growth strategies for the company.
Feb 27- Valeant Pharmaceuticals International Inc sees close to 50 opportunities for mergers or acquisitions, its chief executive said on Thursday, as it aims to become one of the world's five biggest pharmaceutical companies.
Feb 27- Valeant Pharmaceuticals International Inc, Canada's largest listed drugmaker, swung to a quarterly profit driven by the acquisition of contact lens maker Bausch& Lomb Holdings Inc.. Valeant's net income attributable to the company was $123.8 million, or 36 cents per share, for the fourth quarter ended Dec. 31.
Lawyers for Charles Warner and Clayton Lockett fear the men could suffer severe pain if Oklahoma is allowed to maintain a "veil of secrecy." A hearing on that will be held Tuesday before District Judge Patricia Parrish in Oklahoma City; clemency hearings set for this week and next week remained on the Parole and Pardon Board's schedule Wednesday..
Feb 27- Valeant Pharmaceuticals International Inc, Canada's largest listed drugmaker, reported a quarterly profit compared with a year-earlier loss, mainly driven by its acquisition of contact lens maker Bausch+ Lomb Holdings Inc..
FRANKFURT, Feb 27- Bayer said it would buy privately held Dihon Pharmaceutical Group Co, a maker of traditional herbal Chinese medicines, as the German drugmaker pushes to become the world's largest non-prescription medicines group.
NEW YORK-- Moody's Investors Service upgraded Biogen Idec's credit rating on Wednesday, saying the biotech drugmaker should continue to report strong sales of its multiple sclerosis drugs. The firm said Biogen Idec Inc. has a strong credit metrics and a solid market position in multiple sclerosis, as treatments for the disease provide most of its revenue.
New pill treatments show better cure rates and fewer side effects. Here are the companies behind those therapies.
InterMune president & CEO Dan Welch says positive drug trial results bring hope to patients with idiopathic pulmonary fibrosis, and discusses the volatility in its stock.
CNBC's Morgan Brennan reports the pharmaceutical companies are developing oral therapies for the condition that could replace current treatments.